LightDeck Diagnostics Receives $2M for Development of Respiratory Illness Inflammation Test
LightDeck Diagnostics received a $2 million contract for the development of a rapid, quantitative, multiplexed test for inflammatory markers.
Read MorePosted by Andy Lundin | Jan 27, 2022 | Diagnostic Technologies, Respiratory Disease |
LightDeck Diagnostics received a $2 million contract for the development of a rapid, quantitative, multiplexed test for inflammatory markers.
Read MorePosted by Andy Lundin | Jan 26, 2022 | Fertility Testing |
The new method could significantly improve diagnosis of male infertility, which is more important than ever now that infertility rates are mounting.
Read MorePosted by Andy Lundin | Jan 18, 2022 | Covid 19, Immunoassay Reagents & test Kits |
In-house wet testing with the virus demonstrated that the LumiraDx SARS-CoV-2 Antigen test detects the Omicron variant.
Read MorePosted by Andy Lundin | Jan 4, 2022 | Company News, Immunoassay Reagents & test Kits, POC Reagents & Test Kits |
The acquisition is expected to streamline the commercialization of the company’s Eikon platform and YourTest PCR device as it nears completion.
Read MorePosted by Andy Lundin | Jan 3, 2022 | Covid 19, Immunoassay Reagents & test Kits |
A high-quality assay that can be used in at-home tests for rapid COVID-19 screening may be just as reliable as the laboratory-based PCR molecular tests.
Read More